Blood-Brain Barrier Transport of Transferrin Receptor-Targeted Nanoparticles
Research output: Contribution to journal › Review › Research › peer-review
Standard
Blood-Brain Barrier Transport of Transferrin Receptor-Targeted Nanoparticles. / Thomsen, Maj Schneider; Johnsen, Kasper Bendix; Kucharz, Krzysztof; Lauritzen, Martin; Moos, Torben.
In: Pharmaceutics, Vol. 14, No. 10, 2237, 2022.Research output: Contribution to journal › Review › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Blood-Brain Barrier Transport of Transferrin Receptor-Targeted Nanoparticles
AU - Thomsen, Maj Schneider
AU - Johnsen, Kasper Bendix
AU - Kucharz, Krzysztof
AU - Lauritzen, Martin
AU - Moos, Torben
PY - 2022
Y1 - 2022
N2 - The blood-brain barrier (BBB), built by brain endothelial cells (BECs), is impermeable to biologics. Liposomes and other nanoparticles are good candidates for the delivery of biologics across the BECs, as they can encapsulate numerous molecules of interest in an omnipotent manner. The liposomes need attachment of a targeting molecule, as BECs unfortunately are virtually incapable of uptake of non-targeted liposomes from the circulation. Experiments of independent research groups have qualified antibodies targeting the transferrin receptor as superior for targeted delivery of nanoparticles to BECs. Functionalization of nanoparticles via conjugation with anti-transferrin receptor antibodies leads to nanoparticle uptake by endothelial cells of both brain capillaries and post-capillary venules. Reducing the density of transferrin receptor-targeted antibodies conjugated to liposomes limits uptake in BECs. Opposing the transport of nanoparticles conjugated to high-affine anti-transferrin receptor antibodies, lowering the affinity of the targeting antibodies or implementing monovalent antibodies increase uptake by BECs and allows for further transport across the BBB. The novel demonstration of transport of targeted liposomes in post-capillary venules from blood to the brain is interesting and clearly warrants further mechanistic pursuit. The recent evidence for passing targeted nanoparticles through the BBB shows great promise for future drug delivery of biologics to the brain.
AB - The blood-brain barrier (BBB), built by brain endothelial cells (BECs), is impermeable to biologics. Liposomes and other nanoparticles are good candidates for the delivery of biologics across the BECs, as they can encapsulate numerous molecules of interest in an omnipotent manner. The liposomes need attachment of a targeting molecule, as BECs unfortunately are virtually incapable of uptake of non-targeted liposomes from the circulation. Experiments of independent research groups have qualified antibodies targeting the transferrin receptor as superior for targeted delivery of nanoparticles to BECs. Functionalization of nanoparticles via conjugation with anti-transferrin receptor antibodies leads to nanoparticle uptake by endothelial cells of both brain capillaries and post-capillary venules. Reducing the density of transferrin receptor-targeted antibodies conjugated to liposomes limits uptake in BECs. Opposing the transport of nanoparticles conjugated to high-affine anti-transferrin receptor antibodies, lowering the affinity of the targeting antibodies or implementing monovalent antibodies increase uptake by BECs and allows for further transport across the BBB. The novel demonstration of transport of targeted liposomes in post-capillary venules from blood to the brain is interesting and clearly warrants further mechanistic pursuit. The recent evidence for passing targeted nanoparticles through the BBB shows great promise for future drug delivery of biologics to the brain.
KW - antibody
KW - blood-brain barrier
KW - endosomal
KW - liposome
KW - nanoparticle
KW - targeting
KW - transferrin
KW - CAPILLARY ENDOTHELIAL-CELLS
KW - MEDIATED TRANSCYTOSIS
KW - ANTIBODY-AFFINITY
KW - DRUG TRANSPORT
KW - IRON
KW - DELIVERY
KW - RAT
KW - EXPRESSION
KW - LIPOSOMES
KW - ALBUMIN
U2 - 10.3390/pharmaceutics14102237
DO - 10.3390/pharmaceutics14102237
M3 - Review
C2 - 36297671
VL - 14
JO - Pharmaceutics
JF - Pharmaceutics
SN - 1999-4923
IS - 10
M1 - 2237
ER -
ID: 324657185